Lowest-Rated StocksLowest-RatedNASDAQ:IART Integra LifeSciences (IART) Stock Price, News & Analysis $13.26 -0.30 (-2.18%) Closing price 03:59 PM EasternExtended Trading$13.26 +0.00 (+0.04%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Integra LifeSciences Stock (NASDAQ:IART) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Integra LifeSciences alerts:Sign Up Key Stats Today's Range$13.16▼$13.7950-Day Range$11.84▼$16.6452-Week Range$8.70▼$20.49Volume826,610 shsAverage Volume933,203 shsMarket Capitalization$1.03 billionP/E Ratio77.97Dividend YieldN/APrice Target$16.13Consensus RatingReduce Company Overview Integra LifeSciences is a medical technology company that develops products for neurosurgery, surgical care and tissue repair. Its offerings include devices and instruments used in cranial surgery, neuromonitoring and wound reconstruction, as well as materials designed to support the repair or regeneration of tissue. The company’s product portfolio includes dural repair products, cranial stabilization systems, surgical instruments and dermal regeneration products. Integra serves hospitals, surgeons and other healthcare providers in the United States and international markets. Founded in 1989, Integra has grown through the development and addition of medical technology businesses and product lines. Its operations focus on providing specialized technologies for surgical and critical-care settings.AI Generated. May Contain Errors. Read More Integra LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreIART MarketRank™: 2.03574363188 of 5 starsIntegra LifeSciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 637th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingReduce Consensus RatingIntegra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.90, and is based on no strong buy ratings, 2 buy ratings, 5 hold ratings, and 3 sell ratings.Upside PotentialIntegra LifeSciences has a consensus price target of $16.13, representing about 20.8% upside from its current price of $13.35.Amount of Analyst CoverageIntegra LifeSciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Integra LifeSciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth1.28% Earnings GrowthEarnings for Integra LifeSciences are expected to grow by 1.28% in the coming year, from $2.34 to $2.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Integra LifeSciences is 78.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Integra LifeSciences is 78.45, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.64.Price to Earnings Growth RatioIntegra LifeSciences has a PEG Ratio of 0.99. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioIntegra LifeSciences has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.55% of the float of Integra LifeSciences has been sold short.Short Interest Ratio / Days to CoverIntegra LifeSciences has a short interest ratio ("days to cover") of 6.37.Change versus previous monthShort interest in Integra LifeSciences has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntegra LifeSciences does not currently pay a dividend.Dividend GrowthIntegra LifeSciences does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Integra LifeSciences this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 1 people have added Integra LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Integra LifeSciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.84% of the stock of Integra LifeSciences is held by insiders.Percentage Held by Institutions84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Integra LifeSciences' insider trading history. Receive IART Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IART Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IARTNovember 19 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IARTNovember 17 at 6:16 PM | globenewswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 20 at 1:00 AM | Weiss Ratings (Ad)Integra LifeSciences Holdings Corporation (IART) - What Are Brokerages Thinking About This Stock?November 12, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IARTNovember 10, 2026 | globenewswire.comIntegra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference TranscriptNovember 10, 2026 | seekingalpha.comIntegra LifeSciences (IART) Stock Could Be A Bargain Based On Cash FlowNovember 6, 2026 | finance.yahoo.comIntegra LifeSciences to Present at the 2026 UBS Global Healthcare ConferenceNovember 6, 2026 | globenewswire.comSee More Headlines IART Stock Analysis - Frequently Asked Questions How have IART shares performed this year? Integra LifeSciences' stock was trading at $12.42 at the beginning of the year. Since then, IART shares have increased by 7.4% and is now trading at $13.3450. How were Integra LifeSciences' earnings last quarter? Integra LifeSciences Holdings Corporation (NASDAQ:IART) announced its quarterly earnings data on Wednesday, October, 21st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.56 by $0.03. The life sciences company had revenue of $411.18 million for the quarter, compared to analysts' expectations of $413.16 million. Integra LifeSciences had a trailing twelve-month return on equity of 18.63% and a net margin of 0.79%. Read the conference call transcript. When did Integra LifeSciences' stock split? Integra LifeSciences's stock split on the morning of Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Integra LifeSciences have any subsidiaries? The following companies are subsidiaries of Integra LifeSciences: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and others. Who are Integra LifeSciences' major shareholders? Integra LifeSciences' top institutional investors include State Street Corp (3.88%), Goldman Sachs Group Inc. (2.03%), Access Investment Management LLC (0.73%) and Leeward Investments LLC MA (0.42%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen and Jeffrey A Graves. View institutional ownership trends. How do I buy shares of Integra LifeSciences? Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Integra LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Gilead Sciences (GILD), Micron Technology (MU), Eli Lilly and Company (LLY), Block (XYZ), Adobe (ADBE), Medtronic (MDT) and Boeing (BA). Company Calendar Last Earnings10/21/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IART's financial health is in the Red zone, according to TradeSmith. IART has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:IART CIK917520 Webwww.integralife.com Phone(609) 275-0500Fax609-750-4277Employees4,427Year Founded1989Price Target and Rating Average Price Target for Integra LifeSciences$16.13 High Price Target$25.00 Low Price Target$13.00 Potential Upside/Downside+22.2%Consensus RatingReduce Rating Score (0-4)1.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$0.17 Trailing P/E Ratio77.85 Forward P/E Ratio5.57 P/E Growth0.99Net Income-$516.47 million Net Margins0.79% Pretax Margin1.35% Return on Equity18.63% Return on Assets5.49% Debt Debt-to-Equity Ratio1.67 Current Ratio3.62 Quick Ratio2.21 Sales & Book Value Annual Sales$1.64 billion Price / Sales0.63 Cash Flow$4.02 per share Price / Cash Flow3.28 Book Value$13.71 per share Price / Book0.96Miscellaneous Outstanding Shares77,800,000Free Float74,813,000Market Cap$1.03 billion OptionableOptionable Beta1.28 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IART) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Integra LifeSciences Holdings Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Integra LifeSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.